GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shan Dong Kexing Bioproducts Co Ltd (SHSE:688136) » Definitions » EBIT

Shan Dong Kexing Bioproducts Co (SHSE:688136) EBIT : ¥-187 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shan Dong Kexing Bioproducts Co EBIT?

Shan Dong Kexing Bioproducts Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥26 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-187 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shan Dong Kexing Bioproducts Co's annualized ROC % for the quarter that ended in Mar. 2024 was 3.28%. Shan Dong Kexing Bioproducts Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 6.99%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shan Dong Kexing Bioproducts Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -4.58%.


Shan Dong Kexing Bioproducts Co EBIT Historical Data

The historical data trend for Shan Dong Kexing Bioproducts Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shan Dong Kexing Bioproducts Co EBIT Chart

Shan Dong Kexing Bioproducts Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 194.45 169.48 103.65 -112.76 -220.94

Shan Dong Kexing Bioproducts Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.56 -46.21 8.83 -175.99 25.98

Competitive Comparison of Shan Dong Kexing Bioproducts Co's EBIT

For the Biotechnology subindustry, Shan Dong Kexing Bioproducts Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shan Dong Kexing Bioproducts Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shan Dong Kexing Bioproducts Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shan Dong Kexing Bioproducts Co's EV-to-EBIT falls into.



Shan Dong Kexing Bioproducts Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-187 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shan Dong Kexing Bioproducts Co  (SHSE:688136) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shan Dong Kexing Bioproducts Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=108.672 * ( 1 - 27.91% )/( (2324.196 + 2449.835)/ 2 )
=78.3416448/2387.0155
=3.28 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3031.093 - 243.268 - ( 568.796 - max(0, 669.995 - 1133.624+568.796))
=2324.196

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3063.871 - 219.93 - ( 542.289 - max(0, 766.641 - 1160.747+542.289))
=2449.835

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Shan Dong Kexing Bioproducts Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=103.9/( ( (1199.761 + max(225.299, 0)) + (1222.083 + max(326.052, 0)) )/ 2 )
=103.9/( ( 1425.06 + 1548.135 )/ 2 )
=103.9/1486.5975
=6.99 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(274.523 + 191.365 + 26.971) - (243.268 + 0 + 24.292)
=225.299

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(341.935 + 178.306 + 34.463) - (219.93 + 0 + 8.7219999999999)
=326.052

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shan Dong Kexing Bioproducts Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-187.397/4090.906
=-4.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shan Dong Kexing Bioproducts Co EBIT Related Terms

Thank you for viewing the detailed overview of Shan Dong Kexing Bioproducts Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Shan Dong Kexing Bioproducts Co (SHSE:688136) Business Description

Traded in Other Exchanges
N/A
Address
No. 2666, Chuangye Road, Mingshui Development Zone, Zhangqiu District, Shandong Province, Jinan, CHN, 250200
Shan Dong Kexing Bioproducts Co Ltd formerly Kexing Biopharmaceutical Co Ltd is an innovative biopharmaceutical company. It is engaged in the production and sales of recombinant protein drugs and probiotics. The company use the drugs in the fields of antiviral, hematology, tumor and immunity, and degenerative diseases.
Executives
Wang Xiao Qin Directors, senior managers
Cui Ning Directors, senior managers
Ma Hong Jie senior management
Shao Ke senior management
Deng Xue Qin Director
Zhao Yan Qing Directors, senior managers

Shan Dong Kexing Bioproducts Co (SHSE:688136) Headlines

No Headlines